XOMA Ltd. (Nasdaq: XOMA) is a biotechnology company focused on the discovery, development and manufacturing of monoclonal antibody-based therapeutics for serious unmet medical needs. XOMA's world-class monoclonal antibody technologies have contributed to the development of marketed biologics with a total of more than $1 billion in annual sales and for which XOMA received substantial royalties.
ANTIBODY CAPABILITIES
 
LATEST NEWS
 
HIGHLIGHTS

XOMA’s extensive antibody expertise includes antibody discovery, optimization, cell line and process development.

 

 

Gevokizumab expanded development program: